Table 1.
Demographic and clinical characteristics of patients.
Figure 1.
Kaplan-Meier analysis using Log-Rank and Breslow tests (clinical remission or mucosal healing was not associated with the time to restarting infliximab therapy in Crohn’s disease).
Figure 2.
Kaplan-Meier analysis using Log-Rank and Breslow tests (clinical remission or mucosal healing was not associated with the time to restarting infliximab therapy in Ulcerative colitis).
Table 2.
Univariate regression analysis of need for retreatment with infliximab therapy.